Schrdinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb; Schrdinger To Receive $55M Upfront And Is Eligible To Receive $2.7B In Milestone Payments Plus Royalties